Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Bioxcel Therapeutics ( (BTAI) ) has provided an announcement.
Bioxcel Therapeutics has made a disclosure in their Current Report on Form 8-K, which includes information under Item 7.01 and is incorporated in Item 8.01, excluding the sixth paragraph.
The most recent analyst rating on (BTAI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Bioxcel Therapeutics stock, see the BTAI Stock Forecast page.
Spark’s Take on BTAI Stock
According to Spark, TipRanks’ AI Analyst, BTAI is a Underperform.
Bioxcel Therapeutics’ stock is rated at the lowest end of the scale due to substantial financial instability, including ongoing losses, high debt, and negative cash flows. Short-term technical indicators and valuation metrics further highlight the current challenges. The company needs to address these financial and operational issues to improve its stock performance.
To see Spark’s full report on BTAI stock, click here.
More about Bioxcel Therapeutics
Average Trading Volume: 9,722,388
Technical Sentiment Signal: Sell
Current Market Cap: $45.27M
For detailed information about BTAI stock, go to TipRanks’ Stock Analysis page.